H.C. Wainwright lowered the firm’s price target on BioMarin (BMRN) to $55 from $60 and keeps a Neutral rating on the shares. The firm says Voxzogo’s Q3 miss reflects order timing as demand remains intact ahead of oral entrants.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BMRN:
- BioMarin Pharmaceutical: Strong Growth Potential Amidst Competitive Challenges
- BioMarin price target lowered to $70 from $90 at Wells Fargo
- BioMarin price target lowered to $80 from $86 at Barclays
- BioMarin Reports Strong Q3 2025 Revenue Growth
- BioMarin Pharmaceutical: Strategic Adjustments and Future Potential Justify Buy Rating Despite Revenue Miss